Medical Advocates
Pegylated Interferon Alfa-2b (PEG-INTRON)
   
HIV/HCV Journal Citations

General Reports
 Dose Ranging Studies
 Adverse Events
 Efficacy
 Therapeutic Strategies



 

  
Peg Inf Alfa-2b HIV/HCV Main Page Main New/Newsworthy  Home Page

Last Update:  January 26, 2015

General Reports
 
Peg Interferon alfa-2b/Ribavirin 
 
         Journal Papers, Abstracts, and Commentaries
 
  Rapid and early virological response to chronic Hepatitis C treatment with IFN {alpha}2b or
PEG-IFN & [alpha]2b plus ribavirin in HIV/HCV co-infected patients.
 Payan C, Pivert A, Morand P, et al 
Gut. 2007 Mar 15
 Abstract
Dose Ranging Studies
 
Peg Interferon alfa2b/Ribavirin
 
  A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The
Hepatitis C Intervention Therapy Group.
 Glue P, Rouzier-Panis R, Raffanel C, et al.
 Hepatology 2000 Sep;32(3):647-53
 Abstract
 Viral Dynamics
 
  Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients
on peginterferon-alfa-2a.
 Nasta P, Gatti F, Puoti M,et al  
AIDS. 2008 Apr 23;22(7):857-61
Abstract
Resistance
 
Adverse Events
     
Minority Genotype 2b Hepatitis C Infection
 
     Peg Interferon alfa-2b/Ribavirin
 
  Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient
treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-alpha 2b and
ribavirin.
 Buckton AJ, Kulasegaram R, Ngui SL, et al
 J Clin Virol. 2007 Jul 11;
 Abstract
 
Cutaneous  Disorders
 
     Peg Interferon alfa-2b/Ribavirin
 
  Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an
HIV-infected patient.
 Bessis D, Charron A, Rouzier-Panis R, et al.
 Eur J Dermatol 2002 Jan-Feb;12(1):99-102
 Abstract
 
Eye Disorders
 
     Peg Interferon alfa-2b/Ribavirin
 
  Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with
peginterferon alpha-2b and ribavirin.
 Farel C, Suzman DL, McLaughlin M, et al
 AIDS. 2004 Sep 3;18(13):1805-1809.
 Abstract
 
Liver Fibrosis
 
     Peg Interferon alfa-2b/Ribavirin
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV
or HCV-HIV co-infection.
 Sarmento-Castro R, Horta A, Vasconcelos O, et al  
J Infect. 2006 Dec 26;
 Abstract

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic
hepatitis C.
 Poynard T, McHutchison J, Manns M, et al.
Gastroenterology 2002 May;122(5):1303-13
 Abstract
 

  
  A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients
awaiting liver transplantation.
 Crippin JS, McCashland T, Terrault N, et al.
 Liver Transpl 2002 Apr;8(4):350-5
 Abstract
 
Weight Loss
 
  A WEEK IN REVIEW FEATURED REPORT
Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin:
incidence and risk factors.
 Bani-Sadr F, Lapidus N, Melchior JC, et al 
J Viral Hepat. 2008 Apr;15(4):255-60.
 Abstract
Therapeutic Strategies
 
Post Liver Transplantation
 
     Peg Interferon alfa-2b/Ribavirin
 
  Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
 Mukherjee S, Rogge J, Weaver L, Schafer DF.et al 
Transplant Proc. 2003 Dec;35(8):3042-4.
Abstract

Peg Inf Alfa-2b HIV/HCV Main Page Main New/Newsworthy  Home Page

Peginterferon Afa-2b
HIV/HCV Journal Citations